Ligence Heart vs Us2.v1
AI Verdict
Choose Ligence Heart if…
Choose Ligence Heart if your cardiology department seeks an AI solution for comprehensive automation of 2D transthoracic echocardiography analysis, including automated strain, spectral, and tissue Doppler measurements, alongside broad disease recognition for conditions like heart failure and valvular heart diseases. It is particularly well-suited for environments that require secure PHI removal during image transfer and robust integration with existing PACS, EHR, and RIS systems.
View Ligence Heart →Choose Us2.v1 if…
Choose Us2.v1 if your priority is a fully automated, 'zero-click' echocardiography analysis that delivers comprehensive structured reports and disease detection in seconds, significantly boosting workflow efficiency. This tool is ideal for high-volume settings demanding real-time processing, comparison to international guidelines, and specific automated detection of conditions like cardiac amyloidosis.
View Us2.v1 →When choosing between Ligence Heart and Us2.v1, cardiologists should consider their specific workflow needs and desired level of automation. Both are FDA-cleared, HIPAA-compliant AI platforms designed to automate 2D transthoracic echocardiography analysis, aiming to enhance diagnostic efficiency and accuracy.
Ligence Heart excels in providing a comprehensive suite of automated measurements, including Area, Distance, Doppler, and Volume quantification, alongside disease recognition for conditions like heart failure and valvular heart diseases. Its key practical difference lies in its detailed feature set, including automated strain, spectral, and tissue Doppler measurements, making it suitable for practices requiring in-depth, automated quantitative analysis across a broader range of echocardiographic parameters. Practices prioritizing extensive automated measurements and disease recognition for various cardiac conditions may find Ligence Heart more aligned with their needs.
Conversely, Us2.v1 distinguishes itself with its “zero-click analysis” and real-time processing, delivering comprehensive structured reports with measurements and disease detection in seconds. This emphasis on speed and minimal user interaction makes it ideal for high-volume clinics where rapid turnaround and workflow efficiency are paramount. While both offer disease detection, Us2.v1 specifically highlights automated detection of cardiac amyloidosis and pulmonary hypertension. Practices seeking the fastest possible automated analysis with a focus on immediate, actionable reports and a streamlined workflow would likely benefit most from Us2.v1.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Ligence Heart | Us2.v1 |
|---|---|---|
| Pricing | Contact-for-pricing | Volume-based pricing model. |
| Deployment | Cloud-based; on-premise; hybrid | Cloud, On-premise, Hybrid solution |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Ligence Heart | Us2.v1 |
|---|---|---|
| Product Name | Ligence Heart | Us2.v1 |
| Company | Ligence | eko.ai Pte. Ltd. d/b/a Us2.ai |
| Core Automation Focus | Automates the analysis and reporting of 2D transthoracic echocardiography. | Fully automated AI software for echocardiography analysis. |
| Specific Disease Detection | Heart failure, cardiomyopathy, pulmonary hypertension, valvular heart diseases. | Cardiac amyloidosis, pulmonary hypertension. |
| Report Generation Detail | Automated calculation of measurements and report generation. | Comprehensive structured reports with measurements, disease detection, and findings; editable annotations and conclusions; comparison to international reference guidelines. |
Videos
Demos, reviews, and walkthroughs featuring Ligence Heart and Us2.v1.